Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity.
Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity.
复制标题
DOI：
10.1016/j.gendis.2017.07.007
复制
发表时间：
2017-09
期刊：
影响因子：
6.8
通讯作者：
Tang SC
中科院分区：
文献类型：
--
作者：
Sadek I;Keaton M;Maihle NJ;Tang SC
人表皮生长因子受体2（HER 2）在25%-30%的乳腺癌患者中过表达。抗HER 2疗法改变了HER 2+乳腺癌的侵袭性进程。尽管有治疗益处，但它们的心脏毒性是主要问题，特别是当与蒽环类药物同时使用时。在这里，我们提出了一个复发性HER 2+乳腺癌的老年患者。由于体格检查结果以及曲妥珠单抗诱导的重度心脏毒性病史，她的复发性疾病表现不常见，同时需要额外的抗HER 2治疗。她接受新辅助抗HER 2治疗III期乳腺癌。由于心脏射血分数（EF）严重降低，她仅接受了5次辅助性曲妥珠单抗给药。不幸的是，她的疾病复发一年后，胸壁病变和持续低EF。我们用拉帕替尼联合卡培他滨治疗患者，使其胸壁病变迅速消退。更重要的是，患者的疾病得到了一年的控制，射血分数没有恶化。我们讨论了复发性HER 2+乳腺癌伴胸壁疾病的管理，以及有曲妥珠单抗诱导心功能不全病史的患者抗HER 2治疗的选择。
The human epidermal growth factor receptor 2 (HER2) is overexpressed in 25%–30% of breast cancer patients. Anti-HER2 therapies have changed the aggressive course of HER2+ breast cancer. In spite of the therapeutic benefits, their cardiotoxicities are major concerns, especially when used concurrently with anthracyclines. Here we present an elderly patient with relapsed HER2+ breast cancer. Her presentation for relapsed disease was unusual for the physical finding as well as the history of trastuzumab-induced severe cardiotoxicity while requiring additional anti-HER2 therapy. She received neoadjuvant anti-HER2 treatment for stage III breast caner. Due to severe reduction of cardiac ejection fraction (EF), she only received five doses of adjuvant transtuzumab. Unfortunately her disease relapsed one year later with chest wall lesions and a persistent low EF. We treated the patient with lapatinib combined with capecitabine which resulted rapid resolution of her chest wall lesion. More importantly, the patient had one year of disease control without deterioration in her ejection fraction. We discussed the management of recurrent HER2+ breast cancer with chest wall disease and the choice of anti-HER2 therapy in patients with a history of transtuzumab-induced cardiac dysfunction.
登录
查看更多内容
影响因子：
5
作者：
Kuramochi, Yukio;Guo, Xinxin;Sawyer, Douglas B.
通讯作者：
Sawyer, Douglas B.
影响因子：
45.3
作者：
Di Leo, Angelo;Gomez, Henry L.;Press, Michael F.
通讯作者：
Press, Michael F.
影响因子：
51.1
作者：
Untch, Michael;Loibl, Sibylle;von Minckwitz, Gunter
通讯作者：
von Minckwitz, Gunter
影响因子：
3.8
作者：
Rupert, Cassady E.;Coulombe, Kareen L. K.
通讯作者：
Coulombe, Kareen L. K.
DOI：
10.1016/j.bbamcr.2016.01.021
发表时间：
2016-07-01
影响因子：
5.1
作者：
Ghigo, Alessandra;Li, Mingchuan;Hirsch, Emilio
通讯作者：
Hirsch, Emilio